1 Enterprise Drive
Suite 430
Shelton, CT 06484-4779
United States
203-221-7381
https://www.intensitytherapeutics.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 5
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Lewis H. Bender M.A., M.B.A., M.S. | Founder, President, CEO & Chairman of the Board | 1.1M | N/D | 1959 |
Mr. John Wesolowski CPA, M.B.A. | Principal Accounting Officer & Controller | 272.37k | N/D | 1960 |
Mr. James M. Ahlers | Executive Vice President of Corporate Finance | 75.09k | N/D | 1964 |
Mr. Joseph Talamo CPA, M.B.A. | Chief Financial Officer | N/D | N/D | 1969 |
Mr. Brian Schwartz M.D. | Executive Vice President of Clinical Development | N/D | N/D | N/D |
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs in the United States. Its lead product candidate includes INT230-6, which is in human clinical studies for the treatment of refractory solid tumors, such as soft tissue sarcoma which is in phase 3 trails; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
La calificación ISS Governance QuickScore de Intensity Therapeutics, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.